RecruitingPhase 3NCT05835310
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Intervention
- Anifrolumab(biological)
- Enrollment
- 100 target
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- Research Site, Phoenix, Arizona, United States
- Research Site, Los Angeles, California, United States
- Research Site, Washington D.C., District of Columbia, United States
- Research Site, Chicago, Illinois, United States
- Research Site, New Orleans, Louisiana, United States
- Research Site, Bethesda, Maryland, United States
- Research Site, Saint Paul, Minnesota, United States
- Research Site, New Hyde Park, New York, United States
- Research Site, New York, New York, United States
- Research Site, The Bronx, New York, United States
- Research Site, Valhalla, New York, United States
- Research Site, Durham, North Carolina, United States
- Research Site, Cincinnati, Ohio, United States
- Research Site, Cleveland, Ohio, United States
- Research Site, Columbus, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05835310 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGPHASE2NCT05538208The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGNANCT06586710Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLEMeyer Children's Hospital IRCCS
- RECRUITINGPHASE2NCT05039619A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsHoffmann-La Roche
- ACTIVE NOT RECRUITINGPHASE2NCT04179032Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)GlaxoSmithKline